1. What Is the Candidiasis Market?
The Candidiasis Market covers the antifungal treatments for the Candida infections. The infections range from the superficial mucocutaneous candidiasis of the oropharynx, the oesophagus, the vulvovagina, and the skin. The invasive candidiasis and the candidaemia develop in the hospitalised immunocompromised patient. Candidiasis treatment uses the topical azoles for the mucocutaneous candidiasis and the fluconazole for the vaginal and oropharyngeal candidiasis. The echinocandin caspofungin, micafungin, and anidulafungin provide the preferred treatment for the invasive candidiasis and the candidaemia. The preference comes from the superior clinical success rate over the fluconazole in the Candida glabrata and azole-resistant species. The candidiasis market is advancing with the rezafungin ACX-362E once-weekly echinocandin. The STRIVE Phase III trial demonstrated the non-inferior clinical success at day 14 compared with the daily caspofungin for the candidaemia and the invasive candidiasis. The weekly dosing reduces the treatment burden.
2. Candidiasis Market Size & Forecast
3. Emerging Technologies
- Echinocandin glucan synthase inhibitor mechanism blocks the beta-1,3-glucan synthesis that the Candida cell wall requires. The mechanism provides the fungicidal candidacidal activity that the azole fungistatic mechanism cannot achieve for the Candida biofilm. The azole resistance in the Candida glabrata and Candida krusei makes the echinocandin the preferred treatment.
- Rezafungin once-weekly echinocandin STRIVE Phase III demonstrated non-inferior 14-day clinical success rate 79.3 versus 73.7 percent versus daily caspofungin. The weekly dosing enables the outpatient intravenous treatment. The daily echinocandin outpatient administration requires the OPAT programme to manage.
- Candida auris emergence as the multidrug-resistant Candida species resists the fluconazole in greater than 90 percent of isolates, the echinocandin in 5 percent, and the polyene amphotericin B in 35 percent. The resistance creates the pan-resistant isolate. The WHO critical pathogen designation identifies the species as the priority antifungal research target.
- Oropharyngeal candidiasis HIV-associated arises when the CD4 count falls below 200 cells per microlitre. The fluconazole prophylaxis debate stems from the drug interaction with the ART. The chronic fluconazole selects the azole resistance in the HIV patient.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Aspergillosis Market.
4. Key Market Opportunity
One of the most substantial opportunities in the Candidiasis market is rezafungin once-weekly long-acting echinocandin adoption providing dosing convenience over daily echinocandins, where outpatient and step-down therapy benefits drive prescribing growth. Cidara Therapeutics and Mundipharma capture this convenience-driven opportunity. A parallel growth driver is driven by ibrexafungerp indication expansion. As rezafungin adoption proceeds and ibrexafungerp expansion advances, the addressable opportunity is evolving from daily echinocandin-dominant therapy toward weekly long-acting and oral triterpenoid options.
5. Top Companies in the Candidiasis Market
The following organisations hold leading positions in the Candidiasis Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Pfizer
- Astellas Pharma
- Merck
- Scynexis
- Cidara Therapeutics
- F2G
- Bayer
- Sun Pharma
6. Market Segmentation
The Candidiasis Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Drug Class | EchinocandinTriazolePolyeneTriterpenoid |
| By Drug | CaspofunginMicafunginAnidulafunginRezafunginFluconazoleIbrexafungerp |
| By Setting | Invasive CandidiasisCandidemiaMucocutaneous |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Candidiasis Market trajectory over the forecast period:
Echinocandin Glucan Synthase Inhibitor Fungicidal Activity Against Candida Biofilm and Azole-Resistant Non-Albicans Species Including C.Glabrata and C. krusei Has Established the Echinocandin as the Preferred Invasive Candidiasis and Candidaemia Treatment Over the Azole Fungistatic Mechanism. The IDSA recommendation of echinocandin first-line therapy for candidaemia in moderately-to-severely ill patients and those with prior azole exposure reflects the rising Candida glabrata and non-albicans species prevalence in invasive candidiasis that are characterised by fluconazole minimum inhibitory concentrations above the susceptibility breakpoint. Pfizer's caspofungin Cancidas, Astellas Pharma's micafungin Mycamine, and Merck's anidulafungin Eraxis collectively generate approximately USD 800 million annually in echinocandin candidaemia treatment, and generic caspofungin entry following patent expiry has begun the commodity transition in a class where branded differentiation between individual echinocandins is minimal given equivalent efficacy evidence. The candidaemia mortality of approximately 30-40% despite antifungal therapy reflects the critical illness of affected patients rather than drug failure, and source control through central catheter removal remains as important as antifungal selection in determining clinical outcomes.
Rezafungin Once-Weekly Echinocandin STRIVE Phase III Non-Inferior 79.3 Versus 73.7 Percent 14-Day Clinical Success Versus Daily Caspofungin Has Enabled the Weekly Outpatient IV Candidaemia Treatment Eliminating the Daily OPAT Programme That Conventional Echinocandin Requires.Cidara Therapeutics's rezafungin ReSTORE Phase 3 across 187 patients demonstrated 73.2% day-30 all-cause survival versus 76.4% for caspofungin, meeting the pre-specified non-inferiority margin in a population with a mean APACHE II score of 14 indicating moderate severity of illness. The 130-hour half-life of rezafungin from extensive plasma protein binding enables the once-weekly dosing schedule that creates outpatient parenteral antimicrobial therapy possibilities for candidaemia management that daily echinocandin infusion cannot achieve in standard OPAT models. Cidara's commercial strategy positions rezafungin for the step-down treatment period after initial candidaemia control where once-weekly clinic visits are clinically appropriate and substantially reduce the patient and healthcare system burden of completing the recommended 14-day minimum candidaemia treatment course.
Candida auris WHO Critical Pathogen 90 Percent Fluconazole Resistance and 35 Percent Amphotericin Resistance Producing Pan-Resistant Isolates Has Established the Multidrug-Resistant Candida as the Priority Antifungal Research Target That Existing Drug Classes Cannot Reliably Cover.CDC's designation of Candida auris as an urgent antimicrobial resistance threat reflects its combination of pan-azole, frequent echinocandin, and occasional amphotericin resistance that limits treatment to a single drug class in many cases, and its ability to persist on environmental surfaces for weeks enables ICU outbreaks requiring aggressive environmental decontamination that is technically more demanding than bacterial pathogen outbreak control. Echinocandin therapy achieves clinical response in approximately 70% of C. auris infections when the minimum inhibitory concentration is below the susceptibility breakpoint, but echinocandin-resistant C. auris emergence is being reported from ICUs in India, Spain, and the US where prolonged echinocandin exposure in critically ill patients selects for higher-MIC isolates. Ibrexafungerp's activity against azole-resistant C. auris including isolates with elevated echinocandin MIC provides a treatment option for the most resistant C. auris cases, and fosmanogepix APX001, an Fks inhibitor from Amplyx Pharmaceuticals being acquired by Pfizer, is advancing in Phase 2 with in vitro activity against C. auris that expands the treatment arsenal.
For related market intelligence, see the Antifungal Drug Market.
8. Segmental Analysis
By drug class, the echinocandin segment dominated the Candidiasis Market in 2025, as Pfizer's Cancidas and Astellas Pharma's Mycamine anchored intravenous treatment of invasive candidiasis, generating the largest share of the indication's revenue in hospital care.
By setting, the community and oral-therapy segment is projected to register the highest growth rate through 2034, as Scynexis's Brexafemme and ibrexafungerp oral formulations address fluconazole-resistant vulvovaginal candidiasis and the growing Candida auris threat that drives need for agents beyond existing antifungal classes.
9. Regional Analysis
Regional demand patterns across the Candidiasis Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Candidiasis Market in 2025, accounting for approximately 46% of global revenue, due to US premium pricing for echinocandins, rezafungin, and ibrexafungerp and the broad invasive candidiasis prescribing. Moreover, rezafungin once-weekly adoption and ibrexafungerp launch are most advanced in the US. In addition, echinocandin first-line preference is established. Regional dominance is attributed to this combination of pricing environment and novel antifungal launches.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Candidiasis Market through 2034, driven by expanding access to echinocandins and emerging long-acting antifungals across Asia Pacific healthcare systems. The region is also witnessing rezafungin adoption growing. Moreover, candidemia surveillance is expanding. The combination of these demand drivers and access expansion positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Candidiasis Market was valued at USD 1.48 Bn in 2025 and is projected to reach USD 2.82 Bn by 2034, growing at a CAGR of 7.4% over the 2026–2034 forecast period.
The Candidiasis Market is projected to grow at a CAGR of 7.4% from 2026 to 2034.
North America dominated the Candidiasis Market in 2025, accounting for approximately 46% of global revenue, due to US premium pricing for echinocandins, rezafungin, and ibrexafungerp and the broad invasive candidiasis prescribing.
The leading companies in the Candidiasis Market include Pfizer, Astellas Pharma, Merck, Scynexis, Cidara Therapeutics, F2G, Bayer, Sun Pharma.
Echinocandin glucan synthase inhibitor fungicidal activity against candida biofilm and azole-resistant non-albicans species including c.
By drug class, the echinocandin segment dominated the Candidiasis Market in 2025, as Pfizer's Cancidas and Astellas Pharma's Mycamine anchored intravenous treatment of invasive candidiasis, generating the largest share of the indication's revenue in hospital care.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.